ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Exagen (XGN)
Exagen stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · NASDAQ
$7.79▲ +4.28%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Exagen in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Exagen
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Exagen a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $6.86 and $8.62; in 9 out of 10, between $5.60 and $10.56. Estimated annual volatility is 64%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $198M
- 52-week high
- $11.92
- 52-week low
- $2.59
- Revenue (12 months)
- $71.1M
- Revenue growth (YoY)
- +19.7%
- Gross margin
- 58.3%
- Operating margin
- -21.1%
- Net margin
- -30.0%
- Return on equity
- -113.8%
- Free cash flow (12 months)
- $-1.6M
- Beta
- 2.10
What this means
ATLAS does not publish a fair value for XGN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks XGN has traded between $2.59 and $11.92. Today it is 34.7% below that high and 201% above its low.
On the business: revenue grew 19.7% year over year; net margin is 30.0%.
Its beta is 2.10: it tends to move more than the market, both up and down.
About the company
Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing. It develops and commercializes blood-based laboratory tests under its AVISE brand, supporting clinicians in the diagnosis, prognosis, and monitoring of complex rheumatic and autoimmune conditions.
Want to see everything about Exagen?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Exagen do?
Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease testing. It develops and commercializes blood-based laboratory tests under its AVISE brand, supporting clinicians in the diagnosis, prognosis, and monitoring of complex rheumatic and autoimmune conditions.
What is the chance XGN goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, XGN ends the month between $6.86 and $8.62.
How big is Exagen and what is its P/E ratio?
Exagen's market capitalization is $198M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is XGN?
ATLAS estimates annual volatility at 64%. In a typical month, half of the outcomes end between $6.86 and $8.62.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer